Cardiff Oncology reports Q3 2026 results, preps Phase 3 onvansertib trial for Q1 2027Nov 16Clinical readoutBeiGeneCardiff OncologyUpdated
Seagen/Pfizer's MOUNTAINEER-03 trial for HER2+ colorectal cancer remains active, not recruitingNov 16Trial updatebevacizumabPfizer
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
GSK posts Phase 3b results for Bexsero booster; registers new bioavailability and UC trialsNov 6Weekly roundup, 7 itemsaletekitugbepirovirsenUpdated
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
BeOne Medicines adds Phase 1 trial of BG-92505, a KEAP1 activator, in solid tumorsOct 29Weekly roundup, 3 itemsBeiGenebevacizumabUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
AstraZeneca completes balcinrenone/dapagliflozin PK study; posts two new observational trialsOct 23Weekly roundup, 12 itemsabemaciclibAstraZeneca
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Merck registers Phase 3 ovarian cancer and COPD trials; GT103/Keytruda NSCLC trial results postedOct 16Weekly roundup, 5 itemsDaiichi SankyoensifentrineUpdated
BMS posts RELATIVITY-106 liver cancer results; files two new Phase 1/2 trialsOct 16Weekly roundup, 4 itemsBioNTech SEBristol Myers SquibbUpdated
Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completesOct 16Weekly roundup, 11 itemsacalabrutinibAstraZenecaUpdated
TerSera recalls Zoladex lot over cold-chain lapse; AstraZeneca's EMERALD-2 HCC trial completesOct 8Weekly roundup, 7 itemsAstraZenecaAZD7760Updated
GSK registers three new Phase 3 trials spanning asthma, prostate cancer, ovarian cancerOct 2Weekly roundup, 11 itemscabotegravirganfeboroleUpdated
AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adultsOct 2Weekly roundup, 6 itemsacalabrutinibanifrolumab-fnia
Oncolytics reports faster enrollment in REO 033 colorectal cancer studyOct 1Trial updateCoherus Oncology, Inc.Oncolytics BiotechUpdated
AstraZeneca registers Phase 3 ovarian cancer ADC trial and Phase 1 hMPV antibody studySep 17Weekly roundup, 3 itemsAstraZenecaAZD0543
Incyte registers Phase 3 MAESTRA 3 trial in cyclin E1-overexpressing ovarian cancerSep 1Trial updateINCB123667Incyte Corporation
Merck registers Phase 3 V503 HPV vaccine trial in Chinese females previously given 2vHPV shotAug 28Weekly roundup, 4 itemsbevacizumabDaiichi Sankyo
Merck registers Phase 3 trial testing R-DXd maintenance in advanced ovarian cancerAug 20Trial updateDaiichi SankyoMerck & Co., Inc.
Outlook Therapeutics details LYTENAVA US launch prep in Q3 FY2026 updateAug 14Quarterly updatebevacizumab-vikgOutlook Therapeutics, Inc.
Inhibrx reports Q2 2026 results, sets Q3 PFS readout for INBRX-106Aug 13Quarterly updateInhibrx Biosciences, Inc
Cypherpunk's Leap Therapeutics subsidiary aligns with FDA on Phase 3 trial for sirexatamabAug 12Quarterly updateCypherpunk Technologies Inc.
Adagene reports mid-2026 results, muzastotug data across CRC and HCC trialsAug 12Quarterly updateAdagene Inc
Cardiff Oncology reports Q2 2026 results, plans Phase 3 mCRC trial for early 2027Aug 11Quarterly updateCardiff Oncology
CytomX reports Q2 2026 results, advances Varseta-M toward first registrational studyAug 6Quarterly updateCytomX Therapeutics
Coherus reports Q2 2026 results, flags October data update for tagmokitugAug 5Quarterly updateCoherus Oncology, Inc.toripalimab-tpzi
Outlook Therapeutics posts Phase 3 results for ONS-5010 in wet AMD trialAug 3Trial updatebevacizumabOutlook Therapeutics, Inc.
Merck registers Phase 3 ovarian cancer trial, plus Phase 1 study of MK-1406 in healthy adultsAug 3Weekly roundup, 2 itemsDaiichi SankyoMerck & Co., Inc.
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone
Outlook Therapeutics wins FDA approval for Lytenava in wet AMDJul 24Regulatory decisionbevacizumab-vikgOutlook Therapeutics, Inc.
Outlook Therapeutics grants options and bonuses tied to ONS-5010 BLA progressJul 23PeoplebevacizumabOutlook Therapeutics, Inc.
Outlook Therapeutics posts NORSE THREE results for ONS-5010 in retinal disordersJul 17Trial updatebevacizumabOutlook Therapeutics, Inc.
GSK posts bepirovirsen QT results; registers Mo-Rez ovarian, endometrial Phase 3 trialsJul 10Weekly roundup, 6 itemsbepirovirsencamlipixant
BeiGene's LBL-007/tislelizumab colorectal cancer trial posts resultsJun 30Trial updatealcestobartBeiGene
Outlook Therapeutics posts NORSE EIGHT phase 3 results for ONS-5010 in wet AMDJun 30Trial updatebevacizumabOutlook Therapeutics, Inc.